Products for Research Use Only

PLK1-IN-13

CAT: 0804-HY-173212Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-173212Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
PLK1-IN-13 is a selective and orally active PLK1 inhibitor (IC50: 0.27 nM) . PLK1-IN-13 also inhibits PLK2 (IC50: 12.72 nM) and PLK3 (IC50: 4.12 nM) . PLK1-IN-13 arrests cell at G2 phase, induces apoptosis and down-regulates the transcription of the proliferation-related oncogene c-MYC. PLK1-IN-13 inhibits tumor growth, and can be used for research of acute myeloid leukemia (AML) [1].
CAS Number
3038489-48-1
UNSPSC
12352005
Target
Apoptosis; c-Myc; Polo-like Kinase (PLK)
Related Pathways
Apoptosis; Cell Cycle/DNA Damage
Field of Research
Cancer
Smiles
O=C1N(C)C2=CN=C(NC3=CC=C(C4=NN=C(CN5CCN(C)CC5)S4)C=C3OC)N=C2N(C6CCCC6)[C@@H]1CC
Molecular Formula
C29H39N9O2S
Molecular Weight
577.74
References & Citations
[1]Hou Y, et al. Discovery of novel dihydropteridone derivatives as orally bioavailable PLK1 inhibitors with reduced hERG inhibitory activity for acute myeloid leukemia treatment. Eur J Med Chem. 2025 May 5;289:117480.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
PLK1; PLK2; PLK3